Very accelerated radiotherapy or concurrent chemoradiotherapy for N3 head and neck squamous cell carcinoma: Pooled analysis of two GORTEC randomized trials

Highlights • Outcome of N3 head and neck cancer within two GORTEC phase III trials was analyzed. • 5-year overall survival was 13.8% and worse for T3-4. • No difference between concurrent chemoradiotherapy vs very accelerated radiotherapy. • Oropharyngeal subsite presented high risk of metastasis. •...

Full description

Saved in:
Bibliographic Details
Published in:Oral oncology 2017-08, Vol.71, p.61-66
Main Authors: Tao, Yungan, Aupérin, Anne, Graff, Pierre, Lapeyre, Michel, Grégoire, Vincent, Maingon, Philippe, Geoffrois, Lionel, Verrelle, Pierre, Calais, Gilles, Gery, Bernard, Martin, Laurent, Alfonsi, Marc, Deprez, Patrick, Bardet, Etienne, Pignon, Thierry, Rives, Michel, Sire, Christian, Bourhis, Jean
Format: Article
Language:English
Subjects:
Accelerated radiotherapy
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carcinoma, Squamous Cell - drug therapy
Carcinoma, Squamous Cell - pathology
Carcinoma, Squamous Cell - radiotherapy
Carcinoma, Squamous Cell - therapy
Chemoradiotherapy
Cisplatin - administration & dosage
Concurrent chemoradiotherapy
Disease Progression
Distant metastasis
Female
Fluorouracil - administration & dosage
Head and neck cancer
Head and Neck Neoplasms - drug therapy
Head and Neck Neoplasms - pathology
Head and Neck Neoplasms - radiotherapy
Head and Neck Neoplasms - therapy
Hematology, Oncology and Palliative Medicine
Humans
Male
Middle Aged
Neoplasm Metastasis
Oropharyngeal cancer
Otolaryngology
Prognosis
Squamous Cell Carcinoma of Head and Neck
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Outcome of N3 head and neck cancer within two GORTEC phase III trials was analyzed. • 5-year overall survival was 13.8% and worse for T3-4. • No difference between concurrent chemoradiotherapy vs very accelerated radiotherapy. • Oropharyngeal subsite presented high risk of metastasis. • We observed significant interaction between treatment and subsite.
ISSN:1368-8375
1879-0593
DOI:10.1016/j.oraloncology.2017.06.002